259 related articles for article (PubMed ID: 21653323)
1. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
To-Figueras J; Ducamp S; Clayton J; Badenas C; Delaby C; Ged C; Lyoumi S; Gouya L; de Verneuil H; Beaumont C; Ferreira GC; Deybach JC; Herrero C; Puy H
Blood; 2011 Aug; 118(6):1443-51. PubMed ID: 21653323
[TBL] [Abstract][Full Text] [Related]
2. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.
Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868
[TBL] [Abstract][Full Text] [Related]
3. Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP).
Ducamp S; Schneider-Yin X; de Rooij F; Clayton J; Fratz EJ; Rudd A; Ostapowicz G; Varigos G; Lefebvre T; Deybach JC; Gouya L; Wilson P; Ferreira GC; Minder EI; Puy H
Hum Mol Genet; 2013 Apr; 22(7):1280-8. PubMed ID: 23263862
[TBL] [Abstract][Full Text] [Related]
4. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).
Bishop DF; Tchaikovskii V; Hoffbrand AV; Fraser ME; Margolis S
J Biol Chem; 2012 Aug; 287(34):28943-55. PubMed ID: 22740690
[TBL] [Abstract][Full Text] [Related]
5. Advances in understanding the pathogenesis of congenital erythropoietic porphyria.
Di Pierro E; Brancaleoni V; Granata F
Br J Haematol; 2016 May; 173(3):365-79. PubMed ID: 26969896
[TBL] [Abstract][Full Text] [Related]
6. Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene.
Shady AA; Colby BR; Cunha LF; Astrin KH; Bishop DF; Desnick RJ
Br J Haematol; 2002 Jun; 117(4):980-7. PubMed ID: 12060141
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.
Blouin JM; Duchartre Y; Costet P; Lalanne M; Ged C; Lain A; Millet O; de Verneuil H; Richard E
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18238-43. PubMed ID: 24145442
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
Blouin JM; Ged C; Lalanne M; Lamrissi-Garcia I; Morice-Picard F; Costet P; Daher R; Moreau-Gaudry F; Bedel A; Puy H; Gouya L; Karim Z; Richard E
Blood; 2020 Nov; 136(21):2457-2468. PubMed ID: 32678895
[TBL] [Abstract][Full Text] [Related]
9. Molecular expression, characterization and mechanism of ALAS2 gain-of-function mutants.
Tchaikovskii V; Desnick RJ; Bishop DF
Mol Med; 2019 Jan; 25(1):4. PubMed ID: 30678654
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of uroporphyrinogen III cosynthase gene in Iranian families with congenital erythropoietic porphyria.
Moghbeli M; Maleknejad M; Arabi A; Abbaszadegan MR
Mol Biol Rep; 2012 Jun; 39(6):6731-5. PubMed ID: 22350154
[TBL] [Abstract][Full Text] [Related]
11. Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria.
Bishop DF; Tchaikovskii V; Nazarenko I; Desnick RJ
Mol Med; 2013 Mar; 19(1):18-25. PubMed ID: 23348515
[TBL] [Abstract][Full Text] [Related]
12. A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.
Fontanellas A; Bensidhoum M; Enriquez de Salamanca R; Moruno Tirado A; de Verneuil H; Ged C
Eur J Hum Genet; 1996; 4(5):274-82. PubMed ID: 8946173
[TBL] [Abstract][Full Text] [Related]
13. Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
Blouin JM; Bernardo-Seisdedos G; Sasso E; Esteve J; Ged C; Lalanne M; Sanz-Parra A; Urquiza P; de Verneuil H; Millet O; Richard E
Hum Mol Genet; 2017 Apr; 26(8):1565-1576. PubMed ID: 28334762
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of congenital erythropoietic porphyria: mutations in the human uroporphyrinogen III synthase gene.
Xu W; Astrin KH; Desnick RJ
Hum Mutat; 1996; 7(3):187-92. PubMed ID: 8829650
[TBL] [Abstract][Full Text] [Related]
15. Identification of two new mutations in congenital erythropoietic porphyria.
Bensidhoum M; Ged C; Hombrados I; Moreau-Gaudry F; Hift RS; Meissner P; Sturrock ED; de Verneuil H
Eur J Hum Genet; 1995; 3(2):102-7. PubMed ID: 7552139
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics of congenital erythropoietic porphyria.
Desnick RJ; Glass IA; Xu W; Solis C; Astrin KH
Semin Liver Dis; 1998; 18(1):77-84. PubMed ID: 9516681
[TBL] [Abstract][Full Text] [Related]
17. C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.
Frank J; Wang X; Lam HM; Aita VM; Jugert FK; Goerz G; Merk HF; Poh-Fitzpatrick MB; Christiano AM
Ann Hum Genet; 1998 May; 62(Pt 3):225-30. PubMed ID: 9803266
[TBL] [Abstract][Full Text] [Related]
18. Anti-Correlation between the Dynamics of the Active Site Loop and C-Terminal Tail in Relation to the Homodimer Asymmetry of the Mouse Erythroid 5-Aminolevulinate Synthase.
Na I; Catena D; Kong MJ; Ferreira GC; Uversky VN
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958424
[TBL] [Abstract][Full Text] [Related]
19. Congenital erythropoietic porphyria: prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells.
Kauppinen R; Glass IA; Aizencang G; Astrin KH; Atweh GF; Desnick RJ
Mol Genet Metab; 1998 Sep; 65(1):10-7. PubMed ID: 9787090
[TBL] [Abstract][Full Text] [Related]
20. X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley.
Cotter PD; Rucknagel DL; Bishop DF
Blood; 1994 Dec; 84(11):3915-24. PubMed ID: 7949148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
